DURHAM, N.C., Dec. 17 /PRNewswire/ -- In a recent customer satisfaction survey of over 30,000 readers of ADVANCE for Administrators of the Laboratory, bioMerieux was voted by its customers as the "Top Of Class" winner for the microbiology category. The top-level lab managers and pathologists who subscribe to ADVANCE chose bioMerieux over other clinical laboratory suppliers because of the company's "great customer and technical support," "reliable instruments," and "quick response time."
Results of this survey were announced in the November issue of ADVANCE, with comments from readers on why they selected bioMerieux. The survey was conducted online at http://www.advanceweb.com between mid-June and mid-August, 2008. This year's survey had nearly 1,300 survey responses, primarily from top-level managers.
"The winners of our 'Top Of Class' survey are rated by readers of ADVANCE for Administrators of the Laboratory as the elite in their respective categories," said Lynn Nace, editor of ADVANCE for Administrators of the Laboratory. "And as such, they often raise the standard to improve the quality and accuracy of clinical laboratory testing and results reporting."
Microbiology was one of 13 categories polled by ADVANCE. For each category, readers were asked to fill in the name of the company they felt was top of the class and provide three reasons to support their nominations.
Published by Merion Publications Inc., ADVANCE for Administrators of the Laboratory is a medical laboratory and research specialty publication that boasts over 30,000 readers who manage labs or who support clinical labs. The monthly publication was founded in 1992 and provides original content for managers, directors, pathologists, and supervisors of clinical laboratories. For more information, visit http://www.advanceweb.com.
Advancing diagnostics to improve public health
A world leader in the field of in vitro diagnostics for over 45 years, bioMerieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2007, revenues reached euro 1.063 billion with 84% of sales outside of France.
bioMerieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Our products are used for diagnosing infectious diseases and providing high medical value results for cardiovascular emergencies and cancer screening and monitoring. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
bioMerieux is listed on the NYSE Euronext Paris market (Symbol: BIM - ISIN: FR0010096479). Other information can be found at http://www.biomerieux.com.
Copyright©2008 PR Newswire.
All rights reserved